TOP

The Science Of Creating a Better Tomorrow.

Bringing the power of science to healthcare.

As a life sciences company, Sequenom (NASDAQ: SQNM) has a guiding vision: To improve healthcare by providing revolutionary genomic and genetic analysis solutions for the clinical research and molecular diagnostic markets.

What makes this vision a reality? Our deep commitment to "Quality of Science." For us, only the highest quality is acceptable. We accept nothing less in the science that supports every product and service we offer. From design and development to manufacturing and marketing of innovative technology, instrumentation and tests, "Quality of Science" is the common element in everything we do.

 

 

Sequenom Center for Molecular Medicine (doing business as Sequenom Laboratories), a wholly-owned subsidiary of Sequenom, provides best-in-class laboratory testing services with a focus on prenatal and ophthalmological diseases and conditions. Our services include the market-leading MaterniT21 PLUS noninvasive prenatal laboratory-developed test intended for use in pregnant women at increased risk for fetal aneuploidies. 

 

A division of Sequenom, Inc. that provides technologies and tools for translational research, oncology, agricultural genomics and clinical diagnostics. Sequenom Bioscience's proprietary MassARRAY® System is a high-performance MALDI-TOF mass spectrometry-based DNA analysis platform that delivers reliable and specific data from biological samples and from genetic target material that is only available in trace amounts.

Harry F. Hixson Jr., PhD, MBA Chairman of the Board & Chief Executive Officer

Dr. Hixson serves as Chief Executive Officer and has served as Chairman of the Board of Directors since 2003. He served on the board of directors of BrainCells, Inc., a biopharmaceutical company focused on central nervous system drug development, where he was Chief Executive Officer from July 2004 until September 2005. Dr. Hixson served as Chief Executive Officer of Elitra Pharmaceuticals, Inc., a biopharmaceutical company focused on anti-infective drug development, from February 1998 until May 2003. He served as President and Chief Operating Officer of Amgen Inc., and was a member of its board of directors from 1988 to 1991. Prior to Amgen, Dr. Hixson held various management positions with Abbott Laboratories, including Vice President, Diagnostic Products Business Group, and Vice President, Research and Development in the Diagnostics Division. Dr. Hixson also is a director of Arena Pharmaceuticals, Inc. Dr. Hixson received his PhD in physical biochemistry from Purdue University and an MBA from the University of Chicago.

William Welch, President and Chief Operating Officer

Mr. Welch serves as President and Chief Operating Officer, previously serving as Senior Vice President, diagnostics. Prior to joining Sequenom, Mr. Welch was a consultant to molecular diagnostic companies in the personalized medicine sector. From August 2005 to September 2009, Mr. Welch was Senior Vice President and Chief Commercial Officer at Monogram Biosciences, where he led sales, marketing, commercial operations and pharma alliances for its oncology and virology businesses. Prior to Monogram, Mr. Welch was Vice President of Sales and Marketing at La Jolla Pharmaceuticals and Vice President of Global Marketing at Dade Behring MicroScan. Mr. Welch entered the healthcare industry with Abbott Laboratories where he held positions of increasing responsibility including general management. Mr. Welch received his MBA from Harvard University and a BA degree in chemical engineering from University of California, Berkeley.

Dirk van den Boom, PhD, Executive Vice President, Research & Development and Chief Technology Officer

Dr. van den Boom serves as Executive Vice President, Research and Development and Chief Technology Officer. From October 2009 until December 2012, he led the research and development function as Vice President and then Senior Vice President. He joined Sequenom in 1998 in the company’s Hamburg offices, serving in various management roles within the Sequenom R&D department. Dr. van den Boom received his PhD in biochemistry/molecular biology from the University of Hamburg where he focused on various aspects of nucleic acid analysis with mass spectrometry. Dr. van den Boom has co-authored more than 50 scientific articles and is inventor on 48 patents/patent applications.

Paul V. Maier, Chief Financial Officer

Mr. Maier serves as Sequenom's chief financial officer. Prior to joining Sequenom, Mr. Maier served as Senior Vice President and Chief Financial Officer of Ligand Pharmaceuticals Incorporated from 1992 until January 2007, where he helped build Ligand from a venture stage company to a commercial, integrated biopharmaceutical organization. During his tenure at Ligand, Mr. Maier helped raise over $1 billion in equity and debt financings. Prior to Ligand, Mr. Maier spent six years in various management and finance positions at ICN Pharmaceuticals. Mr. Maier currently serves as a director of Apricus Biosciences and International Stem Cell Corporation. Mr. Maier received his MBA from Harvard University and a BS in business logistics from Pennsylvania State University.

Allan T. Bombard, MD, MBAChief Medical Officer

Dr. Bombard serves as Chief Medical Officer. Additionally, he serves as Visiting Professor, Obstetrics and Gynecology, Albert Einstein College of Medicine and Clinical Professor at the University of California San Diego. Prior to joining Sequenom, Dr. Bombard was Chief Executive Officer at Lenetix Medical Screening Laboratories, Inc. in Mineola, New York. Dr. Bombard was the Chief Medical Officer at Sharp Mary Birch Hospital in San Diego, CA. Before joining Sharp Healthcare, Dr. Bombard was Senior Vice President, Chair and Residency Program Director, Department of Ob/Gyn at Lutheran Medical Center, Brooklyn, NY. Dr. Bombard came to Lutheran Medical Center from Aetna, Inc., where he served as the Western U.S. Medical Director for Women’s Health. Before working for Aetna, he served as Professor & Director, Reproductive Genetics, Department of Ob/Gyn & Women’s Health at Montefiore Medical Center and the Albert Einstein College of Medicine in Bronx, New York. He attained the academic rank of professor at the medical school in 1997.

Dr. Bombard received his MD degree from The George Washington University, an MBA from the University of San Diego, and a BA degree from Colgate University. He completed a residency in Ob/Gyn at Wilford Hall United States Air Force Medical Center in San Antonio, Texas, and his fellowship in clinical genetics at Northwestern University in Chicago, Illinois. Dr. Bombard is board certified in both clinical genetics as well as obstetrics & gynecology.

Dr. Bombard retired from the USAF Reserves in 2002 with the rank of colonel and served in Operation Desert Storm. He is a Founding Fellow of the American College of Medical Genetics, a Fellow of the American College of Obstetricians & Gynecologists, a member of the American Medical Association, and a life member of the American College of Physician Executives. Dr. Bombard serves on a number of national professional committees and has lectured extensively on a variety of women’s health issues including genetic counseling, prenatal screening and diagnosis, the business of medicine, and BRCA screening. His articles have appeared in peer-reviewed medical journals such as the Lancet and the American Journal of Obstetrics & Gynecology.

Michael Monko, Senior Vice President, Bioscience

Mr. Monko serves as Senior Vice President, Biosciences. Prior to joining Sequenom in 2006, he served as Vice President of Sales for Upstate/Chemicon with global sales and management responsibility for more than 100 sales, service and support employees. Previously, he served 19 years at Invitrogen Corporation with a progressive and accomplished career in sales, beginning as a representative and culminating as Senior Director, Sales Force Effectiveness. Mr. Monko received his MBA from Babson College and BS in biochemistry from University of New Hampshire.

Bill Bowen, Senior Vice President and General Counsel 

Mr. Bowen serves as Senior Vice President and General Counsel. Prior to joining Sequenom in 2012, Mr. Bowen served as Senior Vice President and General Counsel at Gen-Probe Incorporated, a San Diego-based molecular diagnostics company. Prior to joining Gen-Probe, Mr. Bowen was a business litigation partner at Luce Forward Hamilton & Scripps, LLP. Mr. Bowen received his JD from the University of Virginia, School of Law and a bachelor’s degree in management from the University of Virginia.

Robin Weiner, Senior Vice President, Quality and Regulatory Affairs

Ms. Weiner serves as Senior Vice President, Quality and Regulatory Affairs. Prior to joining Sequenom, Ms. Weiner was an independent regulatory consultant to biotechnology companies, focusing on regulatory strategy, product submissions and quality management systems. From 2004 to 2007, Ms. Weiner served as Vice President Regulatory & Government Affairs at Biosite Incorporated, leading Biosite’s worldwide product approvals and regulatory compliance activities. Prior to Biosite, Ms. Weiner was with Quidel Corporation, most recently serving as Vice President, Clinical and Regulatory Affairs. Prior to joining Quidel, she held research positions at the Scripps Clinic and Research Foundation and the University of California, San Diego. Ms. Weiner received her MBA from National University and a BA degree in biology from the University of California, San Diego and is currently on the board of Seacrest Foundation. 

Carolyn D. Beaver, Vice President and Chief Accounting Officer

Ms. Beaver serves as Vice President and Chief Accounting Officer. Prior to joining Sequenom, Ms. Beaver was employed with Beckman Coulter, Inc., a global biomedical testing manufacturer (now a subsidiary of Danaher Corporation) where she served as Corporate Vice President, Controller and Chief Accounting Officer until 2011. From 1987 until 2002, Ms. Beaver was a partner with KPMG LLP. Ms. Beaver also currently serves as a director of Commerce National Bank, a position she has held since 2005. Ms. Beaver received her BS in accounting from California State Polytechnic University, Pomona and is a licensed CPA.

Board of Directors

Ernst-Günter Afting, PhD, MD

Dr. Afting has served as a director since 1996. From 1995 until his retirement in 2006, Dr. Afting served as president and chief executive officer of the National Research Center for Environment and Health, GSF-National Research Center for Environment and Health GmbH, a governmental research center in Munich, Germany. From 1993 to 1995, he served as president and chief executive officer of Roussel UCLAF, Paris. He was also a member of the board of the Pharmaceutical Division of Hoechst Group from 1984 to 1993 and was chairman and chief executive officer of the Divisional Pharmaceutical Board of Hoechst from 1992-1993. Dr. Afting was a member of the advisory committee on science and technology to German Chancellor Helmut Kohl from 1996 to 1997 and from 1996 to 2005 was a member of the German National Advisory Committee on Health Research to the State Secretaries of Science, Technology and Health. Dr. Afting has been a member of the medical faculty at the University of Goettingen since 1985. Dr. Afting also is a director of Intercell AG, Enanta Pharmaceuticals, Inc., and Olympus Europa GmbH. He received his Ph.D. in chemistry and M.D. degree from the University of Freiburg/Breisgau, Germany.

Kenneth F. Buechler, PhD

Dr. Buechler has served as a director since 2009. He was President, Chief Scientific Officer and co-founder of Biosite Incorporated. From 1988 to 1994, Dr. Buechler was Biosite's Director of Chemistry. Prior to co-founding Biosite, Dr. Buechler was a senior research scientist for the diagnostics research and development group at Hybritech Incorporated. Dr. Buechler received his PhD in biochemistry and his bachelor’s degree in chemistry from Indiana University. Dr. Buechler also is a director of Quidel Corp., Sotera Wireless Inc., and Astute Medical Inc.

John A. Fazio

Mr. Fazio has served as a director since 2007. Mr. Fazio is a former senior general practice partner of PricewaterhouseCoopers, a global accounting and professional services company. Mr. Fazio retired from PricewaterhouseCoopers in 2000 following 35 years of service during which he held a variety of senior positions in accounting, auditing, consulting, and administration at PricewaterhouseCoopers. Mr. Fazio is also a director of Heidrick & Struggles International, Inc. Mr. Fazio received his MA from Ohio State University and his BS from Pennsylvania State University. He is a member of the American Institute of Certified Public Accountants and the Institute of Management Accountants.

David Pendarvis, JD

Mr. Pendarvis has served as a director since 2009. He currently serves as the Chief Administrative Officer and Global General Counsel of ResMed, Inc., a medical device company focused on sleep-disordered breathing. From 2000 until 2002, Mr. Pendarvis was a partner in the law firm of Gray Cary Ware & Freidenrich LLP. From 1986 until 2000, he was a partner with Gibson, Dunn & Crutcher LLP. From 1984 until 1986, he was a law clerk to the Hon. J. Lawrence Irving, US District Judge, Southern District of California. Mr. Pendarvis received his JD from the University of Texas School of Law; a MS in executive leadership from the University of San Diego, and a BA from Rice University.

Harry F. Hixson, Jr., PhD, MBA

Dr. Hixson serves as Chief Executive Officer and has served as Chairman of the Board of Directors since 2003. He served on the board of directors of BrainCells, Inc., a biopharmaceutical company focused on central nervous system drug development, where he was Chief Executive Officer from July 2004 until September 2005. Dr. Hixson served as Chief Executive Officer of Elitra Pharmaceuticals, Inc., a biopharmaceutical company focused on anti-infective drug development, from February 1998 until May 2003. He served as President and Chief Operating Officer of Amgen Inc., and was a member of its board of directors from 1988 to 1991. Prior to Amgen, Dr. Hixson held various management positions with Abbott Laboratories, including Vice President, Diagnostic Products Business Group, and Vice President, Research and Development in the Diagnostics Division. Dr. Hixson also is a director of Arena Pharmaceuticals, Inc. Dr. Hixson received his PhD in physical biochemistry from Purdue University and an MBA from the University of Chicago.

Myla Lai-Goldman, MD

Dr. Lai-Goldman has served as a director since 2012. She is a managing partner at Personalized Science, LLC, Chief Executive Officer of GeneCentric Diagnostics, Inc. and a venture partner with Hatteras Venture Partners. She previously served as Executive Vice President, Chief Medical Officer and Chief Scientific Officer of Laboratory Corporation of America. Dr. Lai-Goldman received her MD degree from Columbia University and an undergraduate degree in biology from the University of Pennsylvania. She completed a pathology residency and surgical pathology fellowship at UCLA in Los Angeles, followed by a hematopathology fellowship at the University of North Carolina at Chapel Hill.

Richard A. Lerner, MD

Dr. Lerner has served as a director since 2007. Dr. Lerner is the former President of the Scripps Research Institute, a private, non-profit biomedical research organization, having served since 1986. Dr. Lerner received the Wolf Prize in Chemistry in 1994, the California Scientist of the Year Award in 1996, the Paul Ehrlich and Ludwig Darmstaedter Prize in 2003, and the Prince of Asturias Award in 2012 for his achievements in the development of catalytic antibodies and combinatorial antibody libraries. Dr. Lerner is a member of the Royal Swedish Academy of Sciences and the National Academy of Sciences. Dr. Lerner currently serves as a director of Kraft Foods, Inc., Opko Health, Inc., Xencor, Inc., and Intra-Collular Therapies. Dr. Lerner received his MD degree from Stanford Medical School.

Charles P. Slacik

Mr. Slacik has served as a director since 2012. He had previously served as Chief Financial Officer and senior Vice President of Finance for Beckman Coulter (now a subsidiary of Danaher Corporation) where he was responsible for all aspects of financial management and information technology. Prior to joining Beckman Coulter, Mr. Slacik was Executive Vice President and Chief Financial Officer at Watson Pharmaceuticals, a specialty pharmaceutical company in Corona, California. Before that, he served as Senior Vice President and Chief Financial Officer at C.R. Bard, Inc., a developer and manufacturer of medical technologies in the fields of vascular, urology, oncology and surgical specialty products. Mr. Slacik received his BS degree in accounting and finance from the University of Connecticut and is a certified public accountant. He is currently a member of the Orange County Chapter of Financial Executives International and the Connecticut Society of CPAs. Mr. Slacik currently serves as a director of STAAR Surgical Company.

Ronald M. Lindsay, PhD

Dr. Lindsay serves as Executive Vice President, Strategic Planning, previously serving as Executive Vice President of Research and Development. Dr. Lindsay has served as a director since 2003. Prior to joining Sequenom, Dr. Lindsay served as Vice President, Research and Development, and Chief Science Officer of diaDexus Inc., a biotechnology company, from 2000 to January 2004. From 1997 through 2000, Dr. Lindsay served in various senior management roles with Millennium Pharmaceuticals, Inc., a biopharmaceutical company. From 1989 to 1997, Dr. Lindsay served in various roles with Regeneron Pharmaceuticals Inc., of which he was a founding scientist. He is also a director of Arqule Inc. Dr. Lindsay received his PhD in biochemistry from the University of Calgary.